ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone207-878-2770
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.99 million
Profitability
Miscellaneous
Employees47
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable
ImmuCell (NASDAQ:ICCC) Frequently Asked Questions
What is ImmuCell's stock symbol?
ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell's earnings last quarter?
ImmuCell Co. (NASDAQ:ICCC) released its earnings results on Monday, November, 11th. The biotechnology company reported ($0.07) EPS for the quarter. The biotechnology company earned $2.97 million during the quarter. ImmuCell had a negative net margin of 15.64% and a negative return on equity of 7.35%. View ImmuCell's Earnings History.
When is ImmuCell's next earnings date?
Has ImmuCell been receiving favorable news coverage?
Media coverage about ICCC stock has trended negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmuCell earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for ImmuCell.
Are investors shorting ImmuCell?
ImmuCell saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,700 shares, an increase of 575.0% from the December 15th total of 400 shares. Based on an average daily volume of 11,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the shares of the company are sold short. View ImmuCell's Current Options Chain.
Who are some of ImmuCell's key competitors?
What other stocks do shareholders of ImmuCell own?
Who are ImmuCell's key executives?
ImmuCell's management team includes the folowing people:
- Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
- Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
- Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
- Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)
How do I buy shares of ImmuCell?
Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ImmuCell's stock price today?
One share of ICCC stock can currently be purchased for approximately $4.96.
How big of a company is ImmuCell?
What is ImmuCell's official website?
How can I contact ImmuCell?
ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]
MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
